| Filed On | Filing |
|---|---|
| 19 Aug 2026 |
8-K/A: Financial Statements and Exhibits
Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 2025 |
| 27 Jul 2026 |
8-K/A: Financial Statements and Exhibits
With Report of Independent Registered Public Accounting Firm |
| 21 Oct 2024 |
8-K/A: Amendments to Articles/Bylaws; Change in Fiscal Year
On October 11, 2024, the Company changed its corporate name to HeartSciences Inc. pursuant to the Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Formation, filed with the Secretary of... |
| 16 May 2024 |
8-K/A: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
To the extent required by Item 3.03 of Form 8-K, the information set forth in Item 5.03 below is incorporated herein by reference. |
| 28 Nov 2023 |
8-K/A: Other Events
On November 22, 2023, Heart Test Laboratories, Inc. (the “Company”) was formally notified by the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has demonstrated compliance with the $2.5 mil... |
| 14 Mar 2023 |
8-K/A: Unregistered Sales of Equity Securities
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURIT... |
| 16 Jun 2022 | 8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more |
Loading...
